Haoyuyu Pharmaceutical (688553.SH) announced on August 6 that the company has recently received the "Pharmaceutical Registration Certificate" issued and approved by the National Medical Products Administration.
Calcium levofolinate can enhance the efficacy and toxicity of fluorouracil (such as 5-fluorouracil) in tumor therapy. Fluorouracil is metabolized into 5-fluoro-2'-deoxyuridine-5'-phosphate (FdUMP), which combines and inhibits thymidylate synthase (an enzyme that is very important in DNA repair and replication). Levoleucovorin can be easily converted into another reduced folate, 5,10-methylenetetrahydrofolate, which can stably bind to deoxyfluorouracil nucleotides and thymidylate synthase in the body, thereby enhancing its inhibitory effect. This product is a folate analogue used in combination with 5-fluorouracil chemotherapy to treat gastric cancer and colorectal cancer.
Methotrexate can inhibit dihydrofolate reductase. Dihydrofolate must be reduced to tetrahydrofolate by this enzyme before it can be used as a carrier of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cell replication. Proliferating tissues such as malignant tumor cells, bone marrow, embryonic cells, oral and intestinal mucosa, and bladder cells are usually more sensitive to the effects of methotrexate. Methotrexate has broad-spectrum anti-tumor activity and can be used alone to treat breast cancer, gestational choriocarcinoma, etc., or in combination with other chemotherapy drugs to treat osteosarcoma, acute leukemia, etc., intrathecal injection is used to treat meningeal metastasis cancer, and psoriasis chemotherapy.